Exelixis, Inc. Aktie News

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced its preliminary unaudited financial results for the fiscal year 2025, provided financial guidance for fiscal year 2026 and delivered an update on its business. Exelixis anticipates 2026 will be a significant year of clinical, regulatory and commercial progress as the company grows its current cabozantinib business, ...

Axsome Therapeutics and Exelixis are generating solid revenue with their current lineups. Both have promising late-stage candidates that should allow them to expand their portfolios.

ALAMEDA, Calif. & AUSTIN, Texas--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) and Natera (Nasdaq: NTRA), a global leader in cell-free DNA and precision medicine, today announced their collaboration on the planned Exelixis-sponsored STELLAR-316 trial. This randomized phase 3 pivotal trial will evaluate zanzalintinib, Exelixis' novel oral kinase inhibitor, with and without an immune checkpoint ...

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that Michael M. Morrissey, Ph.D., the company's President and Chief Executive Officer, will provide a corporate overview at the J.P. Morgan 2026 Healthcare Conference on Monday, January 12, 2026 at 5:15 p.m. PT / 8:15 p.m. ET. To access the webcast link, log onto www.exelixis.com and proceed to the Event Calendar pa...

Exelixis, Inc. (EXEL), an oncology-focused biopharmaceutical firm, is up 81% since a Big Money boost starting in 2021.

Exelixis, Inc. (EXEL) Discusses Strategic Approach to Building Next-Generation Oncology Franchises at R&D Day Transcript

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that it will webcast its virtual event, Exelixis 2025 R&D Day: Building Next-generation Oncology Franchises, on Wednesday, December 10, 2025, from 1:00 p.m. to 3:30 p.m. EST. During the event, featured speakers will review the progress of Exelixis' R&D activities and outline the company's strategy to advance future ...

Axsome Therapeutics boasts a deep late-stage pipeline with billions in potential revenue opportunity. Exelixis' core franchise remains strong while it develops promising new medicines.